BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 8, 2025
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Jiangsu Nhwa Pharmaceutical patents orexin OX2 receptor antagonists for sleep disorders
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/psychiatric
Jiangsu Nhwa Pharmaceutical patents orexin OX2 receptor antagonists for sleep disorders
July 12, 2024
No Comments
Jiangsu Nhwa Pharmaceutical Co. Ltd. has identified orexin OX2 receptor antagonists reported to be useful for the treatment of sleep disorders.
BioWorld Science
Neurology/psychiatric
Patents
